Last reviewed · How we verify
Lidocaine patch local application
Lidocaine patch works by locally blocking sodium channels in nerve cells, which reduces the transmission of pain signals.
The Lidocaine patch is a local anesthetic used for the management of pain associated with post-herpetic neuralgia. It is applied topically to the skin and works by blocking sodium channels in nerve cells, thereby reducing pain signals. The patch is manufactured by Taipei Medical University Hospital and does not have an FDA label. Common side effects include application site reactions, such as redness, itching, and swelling. The drug is generally well-tolerated but has specific contraindications and warnings.
At a glance
| Generic name | Lidocaine patch local application |
|---|---|
| Also known as | Lidopat patch |
| Sponsor | Taipei Medical University Hospital |
| Drug class | Local anesthetic |
| Target | Sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic that acts by inhibiting the influx of sodium ions into nerve cells, which prevents the generation and propagation of action potentials.
Approved indications
Common side effects
- Application site reactions
- Redness
- Itching
- Swelling
Key clinical trials
- Efficacy of Sphenopalatine Block Compared to Blood Patch in the Management of Post-dural Puncture Headaches (PHASE3)
- Evaluation of Percutaneous Cryoneurotomy Compared to Surgical Open Neurotomy for the Management of Equinovarus Foot Deformity in Patients With Refractory Lower Limb Spasticity After Stroke (NA)
- Ethyl Chloride Spray to Reduce Pain From Local Anesthesia During Mohs Micrographic Surgery (EARLY_PHASE1)
- The Comparison of Navigational Bronchoscopic and CT-Guided Preoperative Markings in Minimally Invasive Thoracic Surgery (NA)
- Revised Targets for Knee Radiofrequency Ablation
- The Safety and Efficacy of 5% Lidocaine Patch and Flurbiprofen Patch for Relieving Acute Low Back Pain (PHASE4)
- Comparing CO2 Laser and Electrosurgical Treatments for Perianal Condyloma (NA)
- New Treatments for Actinic Keratoses of the Scalp (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: